Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

被引:9
作者
Zou, Shi [1 ,2 ]
Guo, Wei [3 ,4 ]
Wu, Songjie [2 ,5 ]
Ming, Fangzhao [6 ]
Tan, Yuting [1 ,2 ]
Wu, Mengmeng [1 ,2 ]
Tang, Weiming [7 ,8 ]
Liang, Ke [1 ,2 ,5 ,9 ]
机构
[1] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan, Peoples R China
[2] Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China
[3] Wuhan Univ, Dept Pathol, Zhongnan Hosp, Wuhan, Peoples R China
[4] Wuhan Univ, Sch Basic Med Sci, Dept Pathol, Wuhan, Peoples R China
[5] Wuhan Univ, Dept Nosocomial Infect Management, Zhongnan Hosp, Wuhan, Peoples R China
[6] Wuchang Dist Ctr Dis Control & Prevent, Wuhan, Peoples R China
[7] Guangdong 2 Prov Peoples Hosp, Guangzhou, Peoples R China
[8] Univ North Carolina Chapel Hill Project China, Guangzhou, Peoples R China
[9] Hubei Engn Ctr Infect Dis Prevent Control & Treatm, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
neutralizing antibodies; inactivated COVID-19 vaccine; people living with HIV (PLWH); seroconversion; longitudinal humoral response; DISEASE; 2019; COVID-19; SARS-COV-2; SAFETY; IMMUNOGENICITY; COHORT;
D O I
10.3389/fimmu.2022.988304
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Longitudinal humoral immune response to inactivated COVID-19 vaccines among people living with HIV (PLWH) have not yet been systematically investigated. We conducted a 6-month longitudinal study among vaccinated PLWH and HIV-Negative Controls (HNC) to determine whether the humoral immune response effects of the inactivated COVID-19 vaccine are different between the two groups of people. Totally, 46 PLWH and 38 HNC who received the inactivated COVID-19 vaccine on days 0 and 28 were enrolled. The SARS-CoV-2 neutralizing antibodies (nAbs) and total specific IgM and IgG antibodies were examined on Day 0-Day190. The level and positive seroconversion rate of nAbs peaked on Day 42 in HNC while peaked on Day 70 in PLWH, then decreased gradually with the extension of the vaccination period after the peaks. The peak level of nAbs in PLWH on Day 70, (GMC 8.07 BAU/mL, 95% CI 5.67-11.48) was significantly lower than in HNC on Day 42 (GMC 18.28 BAU/mL, 95% CI 10.33-32.33, P =0.03). The decrease in the geometric mean concentrations (GMCs) of nAbs was observed as 42.9% in PLWH after peak level, which decreased from 8.07 BAU/mL [95% CI: 5.67-11.48] on Day 70 to 4.61 BAU/mL [95% CI: 3.35-6.34] on Day 190 (p = 0.02). On Day 190, only seven (18%, [95% CI: 6-40]) HNC and five (11%, [95% CI: 4-25]) PLWH maintained positive nAbs response respectively. The geometric mean ELISA units (GMEUs) and positive seroconversion rate of IgG in PLWH dropped significantly from Day 70 (GMEUs, 0.20 EU/mL, [95% CI: 0.13-0.34]; seroconversion, 52%, [95% CI: 34-69]) to Day 190 (GMEUs, 0.05 EU/mL, [95% CI: 0.03-0.08], P<0.001; seroconversion, 18%, [95% CI: 8-33], P<0.001). There was no significant difference in levels and seroconversion rates of nAbs and IgG between the two groups on Day 190. The peak immunogenicity of the inactivated COVID-19 vaccine was delayed and inferior in PLWH compared to HNC, while no significant difference was found in six-month immunogenicity between the two groups.
引用
收藏
页数:7
相关论文
共 24 条
  • [1] What do we know about the antibody responses to SARS-CoV-2?
    Alejandro Lagunas-Rangel, Francisco
    Chavez-Valencia, Venice
    [J]. IMMUNOBIOLOGY, 2021, 226 (02)
  • [2] Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
    Ao, Ling
    Lu, Ting
    Cao, Yu
    Chen, Zhiwei
    Wang, Yuting
    Li, Zisheng
    Ren, Xingqian
    Xu, Pan
    Peng, Mingli
    Chen, Min
    Zhang, Gaoli
    Xiang, Dejuan
    Cai, Dachuan
    Hu, Peng
    Shi, Xiaofeng
    Zhang, Dazhi
    Ren, Hong
    [J]. EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 1126 - 1134
  • [3] Severe Covid-19
    Berlin, David A.
    Gulick, Roy M.
    Martinez, Fernando J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2451 - 2460
  • [4] SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review
    Fathizadeh, Hadis
    Afshar, Saman
    Masoudi, Mahmood Reza
    Gholizadeh, Pourya
    Asgharzadeh, Mohammad
    Ganbarov, Khudaverdi
    Kose, Sukran
    Yousefi, Mehdi
    Kafil, Hossein Samadi
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 188 : 740 - 750
  • [5] Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
    Feng, Yanmeng
    Zhang, Yifan
    He, Zhangyufan
    Huang, Haojie
    Tian, Xiangxiang
    Wang, Gang
    Chen, Daihong
    Ren, Yanqin
    Jia, Liqiu
    Wang, Wanhai
    Wu, Jing
    Shao, Lingyun
    Zhang, Wenhong
    Tang, Heng
    Wan, Yanmin
    [J]. ECLINICALMEDICINE, 2022, 43
  • [6] Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
    Frater, John
    Ewer, Katie J.
    Ogbe, Ane
    Pace, Mathew
    Adele, Sandra
    Adland, Emily
    Alagaratnam, Jasmini
    Aley, Parvinder K.
    Ali, Mohammad
    Ansari, M. Azim
    Bara, Anna
    Bittaye, Mustapha
    Broadhead, Samantha
    Brown, Anthony
    Brown, Helen
    Cappuccini, Federica
    Cooney, Enya
    Dejnirattisai, Wanwisa
    Dold, Christina
    Fairhead, Cassandra
    Fok, Henry
    Folegatti, Pedro M.
    Fowler, Jamie
    Gibbs, Charlotte
    Goodman, Anna L.
    Jenkin, Daniel
    Jones, Mathew
    Makinson, Rebecca
    Marchevsky, Natalie G.
    Mujadidi, Yama F.
    Nguyen, Hanna
    Parolini, Lucia
    Petersen, Claire
    Plested, Emma
    Pollock, Katrina M.
    Ramasamy, Maheshi N.
    Rhead, Sarah
    Robinson, Hannah
    Robinson, Nicola
    Rongkard, Patpong
    Ryan, Fiona
    Serrano, Sonia
    Tipoe, Timothy
    Voysey, Merryn
    Waters, Anele
    Zacharopoulou, Panagiota
    Barnes, Eleanor
    Dunachie, Susanna
    Goulder, Philip
    Klenerman, Paul
    [J]. LANCET HIV, 2021, 8 (08): : E474 - E485
  • [7] Impaired antibody response to COVID-19 vaccination in advanced HIV infection
    Hassold, Nolan
    Brichler, Segolene
    Ouedraogo, Elise
    Leclerc, Delphine
    Carroue, Sophie
    Gater, Yamina
    Alloui, Chakib
    Carbonnelle, Etienne
    Bouchaud, Olivier
    Mechai, Frederic
    Cordel, Hugues
    Delagreverie, Heloise
    [J]. AIDS, 2022, 36 (04) : F1 - F5
  • [8] Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China
    Huang, Xiaojie
    Yan, Ying
    Su, Bin
    Xiao, Dong
    Yu, Maohe
    Jin, Xia
    Duan, Junyi
    Zhang, Xiangjun
    Zheng, Shimin
    Fang, Yuan
    Zhang, Tong
    Tang, Weiming
    Wang, Lunan
    Wang, Zixin
    Xu, Junjie
    [J]. VIRUSES-BASEL, 2022, 14 (02):
  • [9] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
    Levy, Itzchak
    Wieder-Finesod, Anat
    Litchevsky, Vladyslav
    Biber, Asaf
    Indenbaum, Victoria
    Olmer, Liraz
    Huppert, Amit
    Mor, Orna
    Goldstein, May
    Levin, Einav Gal
    Hod, Tammy
    Cohen, Carmit
    Lustig, Yaniv
    Rahav, Galia
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (12) : 1851 - 1855
  • [10] Liu YB, 2021, BMC INFECT DIS, V21, DOI [10.1186/s12889-021-11927-x, 10.1186/s12870-021-03229-6, 10.1186/s12879-021-06723-2, 10.1186/s12905-021-01493-0]